SRP6372
Cytidine deaminase human
recombinant, expressed in E. coli, ≥90% (SDS-PAGE)
Synonym(s):
CDA, CDD, Cytidine aminohydrolase, Cytosine nucleoside deaminase
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352200
NACRES:
NA.32
Recommended Products
General description
Cytidine deaminase (CDA) is an enzyme that scavenges exogenous and endogenous cytidine and 2′-deoxycytidine for UMP synthesis. This protein is one of several deaminases responsible for maintaining the cellular pyrimidine pool. CDA also catalyzes the deamination of chemotherapeutic cytosine nucleoside analogs such as arabinofuranosyl cytidine (Ara-C) and 5-azacytidine, which results in the loss of their cytotoxic and antitumor function.
Biochem/physiol Actions
Cytidine deaminase (CDA) is mainly expressed in granulocytes and can form homotetramers. Recombinant human CDA protein, fused to His-tag at N-terminus, was expressed in Escherichia coli and purified by using conventional chromatography.
Physical form
0.5 mg/mL in 20 mM Tris-HCl buffer (pH 8.0) containing 100 mM NaCl, 1 mM DTT, 2 mM EDTA and 40% glycerol.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jia-Ling Ruan et al.
Ultrasound in medicine & biology, 47(6), 1596-1615 (2021-03-13)
In this study we compared three different microbubble-based approaches to the delivery of a widely used chemotherapy drug, gemcitabine: (i) co-administration of gemcitabine and microbubbles (Gem+MB); (ii) conjugates of microbubbles and gemcitabine-loaded liposomes (GemlipoMB); and (iii) microbubbles with gemcitabine directly
Twana Alkasalias et al.
Cell death discovery, 8(1), 464-464 (2022-11-25)
Highly specific and potent inhibitors of dihydroorotate dehydrogenase (DHODH), an essential enzyme of the de novo pyrimidine ribonucleotide synthesis pathway, are in clinical trials for autoimmune diseases, viral infections and cancer. However, because DHODH inhibitors (DHODHi) are immunosuppressants they may
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service